News

This label expansion follows a supplemental New Drug Application (sNDA) submitted by the company. As per the latest approval, the treatment is indicated for reducing risks of major

Following the analysis of cambritaxestat’s chemical and biological properties, including a promising non-clinical safety and efficacy profile, the US regulator granted the ODD status. This designation provides benefits

The fundraising was spearheaded by Enavate Sciences, with Viking Global Investors and Perceptive Advisors joining as new investors. The financing round also saw contributions from all current stakeholders,

This recommendation, part of NICE’s final draft guidance, could potentially benefit nearly 540 adults. A monoclonal antibody, Dostarlimab works by aiding the immune system in combating cancer. Administered

This marks a significant advancement in ophthalmic care, introducing the first FDA-approved ophthalmic formulation of clobetasol propionate, a corticosteroid and the first new steroid in the ophthalmic market

This marks a significant step in the potential approval of the medication for use in the European Union. One application pertains to the treatment of adults with locally

The financing round was led jointly by Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group, with additional contributions from Euclidean Capital and Saisei Ventures. Previously operating

This development is based on pre-clinical findings of the drug in treating pancreatic cancer, a condition with a notably low five-year survival rate and limited treatment options. SNB-101

The facility, which will be operational this month, is designed to meet the increasing demand for life science products in the region. Spanning 13,000m2, the centre is twice